Floatz logo

12 assets in Hepatitis C Virus Infection

Therapeutic assets addressing Hepatitis C Virus Infection, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Velpatasvir
Hepatitis C Virus Infection
Peking University People's HospitalP4A (84)
Ribavirin
Hepatitis C Virus Infection
Peking University People's HospitalP4A (82)
Sofosbuvir
Hepatitis C Virus Infection
Peking University People's HospitalP4A (82)
Voxilaprevir
Hepatitis C Virus Infection
Peking University People's HospitalP4B (63)
Sorafenib
Hepatitis C Virus Infection
Mina Alpha LimitedP2B (62)
Bemnifosbuvir
Hepatitis C Virus Infection
Atea Pharmaceuticals, Inc.P2B (57)
Mtl-Cebpa
Hepatitis C Virus Infection
Mina Alpha LimitedP2B (57)
Ruzasvir
Hepatitis C Virus Infection
Atea Pharmaceuticals, Inc.P2B (57)
Ipilimumab
Hepatitis C Virus Infection
Universita di VeronaP2CCC (53)
Nivolumab
Hepatitis C Virus Infection
Universita di VeronaP2CCC (53)
Hcv Dna Vaccine Ino-8000
Hepatitis C Virus Infection
National Cancer Institute (NCI)P1CC (43)
Rocakinogene Sifuplasmid
Hepatitis C Virus Infection
National Cancer Institute (NCI)P1CC (43)